Tarsus expands its management team

(PRESS RELEASE) IRVINE, Calif. – Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technologies to revolutionize the treatment of patients, starting with patient care. oculars, announced the appointment of José Trevejo, MD, Ph.D., as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of new therapies for serious diseases. Dr. Trevejo’s leadership will be greatly appreciated in the continued advancement of TP-03, the Tarsus pipeline programs in eye care, dermatology, and infectious diseases, and pipeline expansion opportunities.

“We are delighted to welcome Dr. Trevejo to the Tarsus team at this key time in the company’s growth, as we complete the second pivotal clinical trial for our lead investigational product, TP-03, for the treatment of Demodex blepharitis, and if the results are positive, expect to submit a New Drug Application (NDA) later this year,” said Bobak Azamian, MD, Ph.D., President and CEO of Tarsus Pharmaceuticals. “Dr. Trevejo’s leadership in drug development and clinical trials will be instrumental in advancing TP-03 toward FDA approval as well as expanding our broader pipeline. Additionally, his deep infectious disease expertise will be particularly helpful in advancing our novel parasite platform across multiple indications, including our Lyme disease prevention, community-based malaria reduction, rosacea and meibomian gland disease programs.

Prior to joining Tarsus, Dr. Trevejo served as Director of Development at Rocket Pharmaceuticals and CEO of a gene therapy company, SmartPharm. Prior to SmartPharm, he was Vice President of Clinical Development at Cyclerion Therapeutics (formerly a division of Ironwood Pharmaceuticals). Dr. Trevejo joined Cyclerion from Visterra, where he was a member of the leadership team and led the preclinical and clinical development of novel biologics for infectious and rare diseases. Prior to Visterra, he held clinical development positions at Genentech and Vertex Pharmaceuticals.

“I am honored to join Tarsus during this exciting time for the company,” said Dr. Trevejo. “Tarsus has a strong pipeline of therapies in development, and I look forward to advancing clinical programs, contributing to the development of these innovative and highly anticipated therapies, as well as helping to expand the pipeline.”

Dr. Trevejo completed his clinical training, including an infectious disease fellowship after an internal medicine residency at Brigham and Women’s Hospital/Beth-Israel Deaconess Hospital/Harvard Medical School. He earned his MD and Ph.D. degrees from the tri-institutional MD-Ph.D. program at Cornell-Rockefeller-Sloan Kettering in New York.

Comments are closed.